While the Pfizer vaccine became the first to be used in a public vaccination programme on Tuesday, the Oxford/AstraZeneca vaccine team became the first to publish their results in a peer-reviewed journal, the Lancet.
As the press release announcing the results explained, the overall efficacy rate of the Oxford vaccine was measured at 70 per cent, but that concealed a large difference between different arms of the trial.
Already a subscriber? Log in
Subscribe for just $2 a week
Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in